Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Alumis logo — Transforming the lives of patients living with immune-mediat...

Alumis

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

Founded 2021 United States South San Francisco, United States 249 employees Series C Total: $529.00M Biotechnology, Health Care +1

General Information

Company Name Alumis
Founded Year 2021
Location United States South San Francisco, United States
Employees 249
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series C
Business Model B2B, D2C, B2D
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Alumis. To contact Alumis, visit alumis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Alumis compare?

A PDF of Alumis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Alumis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 09, 2026

Alumis announced new Phase 3 data for envudeucitinib at #FallClinical2026, showing rapid, durable reductions in PsO disease burden.

Get alerts when Alumis shows new signals

About Alumis

Alumis, founded in 2021 and headquartered in the United States, is making strides in the biotechnology, health care, and life sciences industries. The company is committed to transforming the lives of patients with immune-mediated diseases through a precise, targeted approach. By focusing on optimizing patient outcomes, Alumis aims to replace broad immunosuppression with therapies tailored precisely to individual patient needs.

Utilizing advanced data analytics, Alumis seeks to innovate patient care by carefully selecting the right targets, molecules, indications, and endpoints. Its mission is further supported by a team of seasoned professionals committed to pioneering transformative therapies.

With a robust financial backing evident in their recent $259.00M Series C investment on 06 March 2024, Alumis is anchored by significant investors like HBM Healthcare Investments, Lilly Asia Ventures, and Foresite Capital, among others. This financial support underscores investor confidence in Alumis' pioneering approach and capacity for innovation in addressing immune dysfunction.

Business keywords: immune-mediated diseases, precision medicine, targeted therapies, drug development, autoimmune diseases, immunology, pharmaceuticals, integrated therapy development, immunosuppression alternatives, patient-centric solutions, disease-specific drug targeting, therapeutic innovation, healthcare analytics

Services & Products

Development of targeted therapies
Clinical trial management
Proprietary data analytics for precision medicine
Patient resources and expanded access policy

Target Customers

Patients with immune-mediated diseases Healthcare providers Medical researchers Investors in biotech and pharmaceutical sectors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $259.00M 10
HBM Healthcare Investments Lilly Asia Ventures Ally Bridge Group
HBM Healthcare Investments, Lilly Asia Ventures +8
06 Mar 2024
Series B $200.00M -
06 Jan 2022
Series A $70.00M -
05 May 2021

Alumis Alternatives & Competitors

View All Alternatives
Alumis vs
3T Biosciences
3T Biosciences United States

3T is an immunotherapy company developing next-generation, transformative therapies for broad patien...

Series A
26 employees
Biopharma, Biotechnology
Compare Alumis vs 3T Biosciences
Alumis vs
Sudo Biosciences
Sudo Biosciences United States

Developing precision TYK2 therapeutics.

Series B
27 employees
Biopharma, Biotechnology
Compare Alumis vs Sudo Biosciences
Alumis vs
ACELYRIN, INC.
ACELYRIN, INC. United States

We are a late-stage clinical biopharma company focused on providing life-changing new treatment opti...

Acquired
103 employees
Biopharma, Biotechnology
Also compare with: Alumis vs GlycoEra AG GlycoEra AG View all alternatives

FAQ About Alumis

Transforming the lives of patients living with immune-mediated diseases using a precision approach.
Alumis was founded in 2021.
Alumis is headquartered in South San Francisco, United States.
Alumis operates in Biotechnology, Health Care and Life Sciences. Its work centres on immune-mediated diseases, precision medicine, targeted therapies and drug development. Its customers include Patients with immune-mediated diseases, Healthcare providers and Medical researchers.
Alumis has a B2B, D2C and B2D business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Alumis has approximately 249 employees.
Alumis has completed 3 funding rounds, raising a total of $529.00M. The latest funding stage is Series C.
Alumis offers: Development of targeted therapies, Clinical trial management, Proprietary data analytics for precision medicine, Patient resources and expanded access policy.
Top alternatives and competitors to Alumis include 3T Biosciences, Sudo Biosciences, ACELYRIN, INC., HI-Bio: A Biogen Company, Entelexo Biotherapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alumis and 3T Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Alumis, https://bouncewatch.com/company/alumis, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes